Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021

Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focusing on mental health and oncology treatments, announced that Dr. Joseph Tucker, CEO, will participate in two upcoming conferences: the A.G.P. Biotech & Specialty Pharma Conference on October 13, 2021, and the KCSA Psychedelics Investor Conference from October 13-14, 2021. Dr. Tucker will present live on October 13 at 11:30 a.m. ET. Interested parties can register for the events through provided links. Enveric is developing innovative treatments using psychedelic-derived molecules and synthetic cannabinoids.

NAPLES, Fla., Oct. 7, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming October conferences:

• A.G.P.'s Biotech & Specialty Pharma Conference to be held virtually on Wednesday, October 13, 2021.
• KCSA Psychedelics Investor Conference to be held virtually at VirtualInvestorConferences.com from October 13-14, 2021. Dr. Tucker will present live on Wednesday, October 13^th at 11:30 a.m. ET. Register to attend here.

For more information about the conferences, or to schedule a one-on-one meeting with Enveric's management team, please contact your representatives directly, or send an email to A.G.P. at agpevents@allianceg.com or KCSA Strategic Communications at envericbio@kcsa.com.

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com 

Media Contacts
Raquel Cona / Joe McIntyre
KCSA Strategic Communications
212.896.1204 / 856.381.8996
rcona@kcsa.com  / jmcintyre@kcsa.com

View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-october-2021-301394758.html

SOURCE Enveric Biosciences

FAQ

What conferences will Enveric Biosciences participate in October 2021?

Enveric Biosciences will participate in the A.G.P. Biotech & Specialty Pharma Conference on October 13, 2021, and the KCSA Psychedelics Investor Conference from October 13-14, 2021.

Who is presenting for Enveric Biosciences at the conferences?

Dr. Joseph Tucker, the CEO of Enveric Biosciences, will present at both conferences.

What is the date and time of Dr. Tucker's presentation?

Dr. Tucker's presentation is scheduled for October 13, 2021, at 11:30 a.m. ET.

How can I register for the Enveric Biosciences conferences?

You can register for the conferences through the links provided in the press release.

What does Enveric Biosciences focus on?

Enveric Biosciences focuses on developing next-generation treatments for mental health and oncology using psychedelic-derived molecules and synthetic cannabinoids.